{"prompt": "['5.1.2.1', 'Administration-Related Reactions, Allergic-Like Reactions,', 'and Hypersensitivity', '59', '5.1.2.2', 'Pulmonary Events', '61', '5.1.2.3', 'Symptomatic Left Ventricular Systolic Dysfunction', '61', '5.1.3', 'Reproductive Risks Associated with Pertuzumab and', 'Trastuzumab', '62', '5.1.3.1', 'Breastfeeding', '63', '5.1.4', 'Management of Patients Who Experience Adverse Events', '63', '5.1.4.1', 'Dose Modifications for Perjeta IV, Herceptin IV, and', 'Pertuzumab and Trastuzumab FDC SC', '63', '5.1.4.2', 'Dose Delays and Treatment Interruption for Perjeta IV,', 'Herceptin IV, and Pertuzumab and Trastuzumab FDC SC', '63', '5.1.4.3', 'Management Guidelines', '64', '5.2', 'Safety Parameters and Definitions', '66', '5.2.1', 'Adverse Events', '66', '5.2.2', 'Serious Adverse Events (Immediately Reportable to the', 'Sponsor)', '66', '5.2.3', 'Adverse Events of Special Interest (Immediately Reportable', 'to the Sponsor)', '67', '5.2.4', 'Selected Adverse Events', '67', '5.2.4.1', 'Heart Failure', '67', '5.2.4.2', 'Asymptomatic Declines in Left Ventricular Ejection Fraction', '68', '5.2.4.3', 'Administration-Related Reactions: Infusion-Related', 'Reactions, Injection-Related Reactions, and-Injection-Site', 'Reactions and Infusion-Site Reactions', '68', '5.3', 'Methods and Timing for Capturing and Assessing', 'Safety Parameters', '69', '5.3.1', 'Adverse Event Reporting Period', '69', '5.3.2', 'Eliciting Adverse Event Information', '70', '5.3.3', 'Assessment of Severity of Adverse Events', '70', '5.3.4', 'Assessment of Causality of Adverse Events', '71', '5.3.5', 'Procedures for Recording Adverse Events', '71', '5.3.5.1', 'Diagnosis versus Signs and Symptoms', '71', '5.3.5.2', 'Adverse Events That Are Secondary to Other Events', '72', '5.3.5.3', 'Persistent or Recurrent Adverse Events', '72', '5.3.5.4', 'Abnormal Laboratory Values', '72', '5.3.5.5', 'Abnormal Vital Sign Values', '73', '5.3.5.6', 'Abnormal Liver Function Tests', '74', '5.3.5.7', 'Deaths', '74', '5.3.5.8', 'Pre-Existing Medical Conditions', '74', '5.3.5.9', 'Lack of Efficacy or Recurrence of Breast Cancer', '75', '5.3.5.10', 'Hospitalization or Prolonged Hospitalization', '75', '5.3.5.11', 'Patient Reported Outcome Data', '75', '5.4', 'Immediate Reporting Requirements from Investigator to', 'Sponsor', '76', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '12 / Protocol MO40628, Version 2']['5.4.1', 'Emergency Medical Call Centre', '76', '5.4.2', 'Reporting Requirements for Serious Adverse Events and', 'Adverse Events of Special Interest', '76', '5.4.2.1', 'Events That Occur Prior to Study Drug Initiation', '76', '5.4.2.2', 'Events That Occur after Study Drug Initiation', '77', '5.4.3', 'Reporting Requirements for Pregnancies', '77', '5.4.3.1', 'Pregnancies in Female Patients', '77', '5.4.3.2', 'Pregnancies in Female Partners of Male Patients', '78', '5.4.3.3', 'Abortions', '78', '5.4.3.4', 'Congenital Anomalies / Birth Defects', '78', '5.4.4', 'Reporting Requirements for Cases of Accidental Overdose or', 'Medication Error', '78', '5.5', 'Follow-Up of Patients after Adverse Events', '79', '5.5.1', 'Investigator Follow-Up', '79', '5.5.2', 'Sponsor Follow-Up', '80', '5.6', 'Adverse Events That Occur after the Adverse Event', 'Reporting Period', '80', '5.7', 'Expedited Reporting to Health Authorities, Investigators,', 'Institutional Review Boards, and Ethics Committees', '80', '6.', 'STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN', '81', '6.1', 'Determination of Sample Size', '81', '6.2', 'Summaries of Conduct of Study', '82', '6.3', 'Summaries of Demographic and Baseline Characteristics', '82', '6.4', 'Primary Endpoint Analysis', '82', '6.5', 'Secondary Endpoint Analyses', '82', '6.5.1', 'Safety Analyses', '82', '6.5.2', 'Efficacy Analyses', '84', '6.6', 'Optional-Interim Analyses', '84', '7.', 'DATA COLLECTION AND MANAGEMENT', '85', '7.1', 'Data Quality Assurance', '85', '7.2', 'Electronic Case Report Forms', '85', '7.3', 'Source Data Documentation', '85', '7.4', 'Use of Computerized Systems', '86', '7.5', 'Retention of Records', '86', '8.', 'ETHICAL CONSIDERATIONS', '86', '8.1', 'Compliance with Laws and Regulations', '86', '8.2', 'Informed Consent', '87', '8.3', 'Institutional Review Board or Ethics Committee', '88', '8.4', 'Confidentiality', '88', '8.5', 'Financial Disclosure', '89', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '13 / Protocol MO40628, Version 2']\n\n###\n\n", "completion": "END"}